Funding for this research was provided by:
Lundbeckfonden (R155-2014-171, R249-2017-1608)
Received: 27 August 2018
Accepted: 28 September 2018
First Online: 8 November 2018
Ethics approval and consent to participate
: All participants provided written consent to participate after receiving written and oral information in accordance with the Declaration of Helsinki of 1964, with subsequent revisions. The study was approved by the Ethics Committee of the Capital Region of Denmark (H-16014580). The study was registered retrospectively at ClinicalTrials.gov (NCT03481400).
: Not applicable.
: MA is a consultant or scientific advisor for Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva, principal investigator for: Amgen 20120178 (Phase 2), 20120295 (Phase 2), 20130255 (Open label extension), 20120297 (Phase 3), 20150308 (Phase 2), ElectroCore GM-11 gamma-Core-R, TEVA TV48125-CNS-30068 (Phase 3), Novartis CAMG334A2301 (Phase 3) and Alder PROMISE-2. MA has no ownership interest and does not hold stock in any pharmaceutical company. MA serves as associated editor of Cephalalgia and co-editor of the Journal of Headache and Pain. SK has acted as invited speaker for Novartis. The remaining authors report no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.